CHMP recommends approval of Isturisa for use in Cushing's Syndrome.- Recordati

Recordati has announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Isturisa (osilodrostat), indicated for the treatment of endogenous Cushing�s syndrome in adults. The benefits with Isturisa are its ability to control or normalise raised cortisol levels. The active substance of Isturisa is osilodrostat, a cortisol synthesis inhibitor. Osilodrostat works by inhibiting 11-beta-hydroxylase, an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. Isturisa will be available as 1-mg, 5-mg and 10-mg film-coated tablets.